Cortisporin®
neomycin 0.35%, polymyxin B, bacitracin, hydrocortisone 1% · ophthalmic ointment
Antibiotic/Steroid
Approved uses
Steroid-responsive ocular inflammation with bacterial infection or a risk of it
Apply the ointment in the affected eye every 3 or 4 hours depending on severity; not more than 8 g initially
Chronic anterior uveitis or corneal injury from burns or foreign bodies, where bacterial infection or a risk of it also exists
Apply the ointment in the affected eye every 3 or 4 hours depending on severity; not more than 8 g initially
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
- Individuals who have shown hypersensitivity to any of its components (hypersensitivity to the antibiotic component occurs at a higher rate than for other components)
Ophthalmic ointment, per gram: neomycin sulfate equivalent to 3.5 mg neomycin base (0.35%), polymyxin B sulfate 10,000 units, bacitracin zinc 400 units, hydrocortisone acetate 10 mg (1%), 3.5 g (1/8 oz) tube
Corticosteroids suppress the inflammatory response to a variety of agents and probably delay or slow healing. Because corticosteroids may inhibit the body's defense mechanism against infection, concomitant antimicrobials may be used when this inhibition is considered clinically significant. Neomycin sulfate and polymyxin B sulfate are active in vitro against susceptible strains of Staphylococcus aureus, streptococci including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens. Neomycin is an aminoglycoside, and aminoglycosides inhibit bacterial protein synthesis by binding to the 30S subunit. Polymyxins disrupt bacterial cell membranes. Bacitracin inhibits cell wall synthesis.
Warnings & Precautions
- Not for injection into the eye: Never to be introduced directly into the anterior chamber of the eye.
- Cutaneous sensitization: Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization, and a precise incidence of hypersensitivity reactions (primarily skin rash) is not known. Manifestations are usually itching, reddening, and edema of the conjunctiva and eyelid, and a sensitization reaction may manifest simply as a failure to heal. Examine periodically during long-term use; discontinue if these signs are observed and avoid products containing these ingredients thereafter.
- Allergic cross-reactions: Allergic cross-reactions may prevent future use of kanamycin, paromomycin, streptomycin, and possibly gentamicin.
- IOP elevation and glaucoma: Prolonged corticosteroid use may cause ocular hypertension or glaucoma with optic nerve damage and defects in visual acuity and fields of vision; monitor IOP routinely once use reaches 10 days, and use with caution where glaucoma is already present, checking IOP frequently.
- Posterior subcapsular cataract: Prolonged corticosteroid use may produce it.
- Corneal and scleral thinning: Long-term topical corticosteroid use and various ocular diseases have been known to cause corneal and scleral thinning; use over already thin tissue may lead to perforation.
- Delayed healing: Ophthalmic ointments may retard corneal wound healing, and corticosteroid use after cataract surgery may delay healing and increase the incidence of filtering blebs.
- Secondary or masked infection: Prolonged use may suppress the host immune response and increase the hazard of secondary ocular infection, and acute purulent infections of the eye may be masked or enhanced by corticosteroid.
- Viral infection exacerbation: Ocular corticosteroids may prolong the course and exacerbate the severity of many viral eye infections including herpes simplex; treating herpes simplex with a steroid requires great caution and frequent slit lamp microscopy.
- Bacterial keratitis: There have been reports of bacterial keratitis associated with topical ophthalmic products in multiple-dose containers inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface. Avoid touching the tip of the tube to eyelids or any other surface; use of the tube by more than one person may spread infection.
- Fungal infections of the cornea: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term corticosteroid applications, so fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate. If signs and symptoms fail to improve after two days, the patient should be re-evaluated.
Common Side Effects
The exact incidence of adverse reactions is not known. Allergic sensitization reactions, including itching, swelling, and conjunctival erythema, occur most often from the anti-infective ingredient; more serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. Reactions due to the corticosteroid component, in decreasing order of frequency, are elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing. Secondary ocular infection has occurred after use of combinations containing corticosteroids and antimicrobials, and fungal and viral infections of the cornea are particularly prone to develop with long-term corticosteroid use. Local irritation on instillation has been reported.
Pregnancy: Category C. Corticosteroids are teratogenic in rabbits applied topically at 0.5% on gestation days 6 to 18 and in mice applied topically at 15% on days 10 to 13. There are no adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether topical administration could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in children have not been established.